Summary

Neuropathic pain (NP) is defined as a disorder of the sensorimotor system and is distinctly different from nociceptive pain, which is a consequence of trauma, injury, or inflammation. The main difference between neuropathic and nociceptive pain is the absence of a continuous nociceptive input in neuropathic pain. Although the term neuropathic pain is used to describe a wide range of pain syndromes with varying etiologies, this report focuses on 3 distinct forms of NP: Painful diabetic neuropathy, Postherpetic neuralgia and trigeminal neuralgia. The main classes of drugs used to treat these three neuropathic pain indications include anticonvulsants, antidepressants, opioids and topical treatments. However, despite the availability of multiple pain medications only 50% of patients respond to any given drug and there are numerous the side effects associated particularly with systemically administered drugs, that reduce their tolerability.

Visit Complete Report Here: http://www.marketresearchreports.biz/analysis-details/topical-clonidine-neuropathic-pain-forecast-and-market-analysis-to-2022

New treatments will target some key unmet needs in terms of efficacy and tolerability, but opportunities will remain for drugs that can more reliably eradicated NP in targeted patient populations, as well as offering an improved safety profile.

BioDelivery Sciences International (BDSI) is currently planning Phase III clinical trials of a Topical Clonidine gel (0.1% clonidine hydrochloride) for the treatment of PDN, after the company entered into a worldwide licensing agreement with Arcion Therapeutics for clonidine in March 2013. Arcion had previously completed Phase II trials of the drug in PDN in December 2009, the results of which showed that it was effective in reducing pain associated with PDN, particularly in subjects with evidence of preserved nociceptors. In September 2010, Arcion Therapeutics received a Fast-Track designation from the FDA for the topical clonidine gel for the treatment of pain associated with PDN.

Download Full Report with TOC:  http://www.marketresearchreports.biz/sample/sample/198423

Scope

- Overview of Neuropathic pain, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Topical Clonidine including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Topical Clonidine for the top six countries from 2012 to 2022.
- Sales information covered for the US, France, Germany, Italy, Spain and the UK.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Neuropathic pain
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Topical Clonidine performance
- Obtain sales forecast for Topical Clonidine from 2012-2022 in the top six countries (the US, France, Germany, Italy, Spain and the UK).

Contact US:

Blog: http://mresearchreports.blogspot.com/

Summary

Clinical trial report, Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Global Clinical Trials Review, H1, 2014" provides data on the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Familial Hypercholesterolemia (Type II Hyperlipoproteinemia). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe.

Visit Complete Report Here: http://www.marketresearchreports.biz/analysis-details/familial-hypercholesterolemia-type-ii-hyperlipoproteinemia-global-clinical-trials-review-h1-2014

The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Familial Hypercholesterolemia (Type II Hyperlipoproteinemia). This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Download Full Report with TOC: http://www.marketresearchreports.biz/sample/sample/198433

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Contact US:

Blog: http://mresearchreports.blogspot.com/

Summary

GlobalData's clinical trial report, Familial Chylomicronemia (Type I Hyperlipoproteinemia) Global Clinical Trials Review, H1, 2014" provides data on the Familial Chylomicronemia (Type I Hyperlipoproteinemia) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Familial Chylomicronemia (Type I Hyperlipoproteinemia). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe.

Visit Complete Report Here: http://www.marketresearchreports.biz/analysis-details/familial-chylomicronemia-type-i-hyperlipoproteinemia-global-clinical-trials-review-h1-2014

The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Familial Chylomicronemia (Type I Hyperlipoproteinemia). This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Download Full Report with TOC: http://www.marketresearchreports.biz/sample/sample/198432

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Contact US:

Blog: http://mresearchreports.blogspot.com/

Summary

GlobalData's clinical trial report, Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) Global Clinical Trials Review, H1, 2014" provides data on the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrades Disease) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrades Disease). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe.

Visit Complete Report Here: http://www.marketresearchreports.biz/analysis-details/familial-amyloid-polyneuropathy-transthyretin-amyloidosis-corino-de-andrades-disease-global-clinical-trials-review-h1-2014

The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrades Disease). This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Download Full Report with TOC: http://www.marketresearchreports.biz/sample/sample/198431

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Contact US:

Blog: http://mresearchreports.blogspot.com/

Summary

Neuropathic pain (NP) is defined as a disorder of the sensorimotor system and is distinctly different from nociceptive pain, which is a consequence of trauma, injury, or inflammation. The main difference between neuropathic and nociceptive pain is the absence of a continuous nociceptive input in neuropathic pain. Although the term neuropathic pain is used to describe a wide range of pain syndromes with varying etiologies, this report focuses on 3 distinct forms of NP: Painful diabetic neuropathy, Postherpetic neuralgia and trigeminal neuralgia. The main classes of drugs used to treat these three neuropathic pain indications include anticonvulsants, antidepressants, opioids and topical treatments. However, despite the availability of multiple pain medications only 50% of patients respond to any given drug and there are numerous the side effects associated particularly with systemically administered drugs, that reduce their tolerability.

Visit Complete Report Here: http://www.marketresearchreports.biz/analysis-details/eslicarbazepine-acetate-neuropathic-pain-forecast-and-market-analysis-to-2022

New treatments will target some key unmet needs in terms of efficacy and tolerability, but opportunities will remain for drugs that can more reliably eradicated NP in targeted patient populations, as well as offering an improved safety profile.

Eslicarbazepine acetate is a drug that was developed by Bial-Portela & Ca., and is currently in Phase III of clinical development for PDN and PHN. It has already been approved for marketing in Europe and the US for the adjunctive treatment of adults with partial epileptic seizures. It was launched in the EU by Bial in conjunction with Eisai in 2009, and received FDA approval in the US in November 2013, where it is being developed and commercialized by Sunovion Pharmaceuticals under the brand name Aptiom.

Download Full Report with TOC: http://www.marketresearchreports.biz/sample/sample/198420

Scope

- Overview of Neuropathic pain, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Eslicarbazepine acetate including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Eslicarbazepine acetate for the top six countries from 2012 to 2022.
- Sales information covered for the US, France, Germany, Italy, Spain and the UK.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Neuropathic pain
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Eslicarbazepine acetate performance
- Obtain sales forecast for Eslicarbazepine acetate from 2012-2022 in the top six countries (the US, France, Germany, Italy, Spain and the UK).

Contact US:

Blog: http://mresearchreports.blogspot.com/

"India Smartphone Market to 2015: Mobile Handset Sales by Technology and by Generation" report provides a top-level overview and detailed insights into the operating environment for mobile operators. It is an essential tool for companies active across the telecom value chain in India and for new companies that may be considering entering the market.

Visit Complete Report Here: http://www.marketresearchreports.biz/analysis-details/india-smartphone-market-to-2015-mobile-handset-sales-by-technology-and-by-generation

Key Findings
- Demographics - Statistical data on India population, households, businesses, nominal GDP, nominal GDP per Capita, consumer price inflation, exchange rates (local currency and US dollar)
- Mobile subscriptions and penetration by population
- Mobile handset sales by quarter
- Mobile handset revenue and average selling price
- Mobile handset sales volume by: type of customer, category, price band, technology and generation, air interface and by feature

Download Full Report with TOC: http://www.marketresearchreports.biz/sample/sample/198092

Synopsis
This report offers a concise breakdown of India operating environment, with both historic data and forecasts to 2015. The report contains quantitative data which covers:

- Demographics - data on India population, households, businesses, nominal GDP, nominal GDP per Capita, consumer price inflation, exchange rates (local currency and US dollar)
- Mobile subscriptions and penetration by population
- Mobile handset sales by quarter
- Mobile handset revenue and average selling price
- Mobile handset sales volume by: type of customer, category, price band, technology and generation, air interface and by feature

Browse Full Report With TOC: http://www.marketresearchreports.biz/analysis/198092

Since 1986, Pyramid Research has compiled an extensive database on the telecommunications markets in Asia, Africa, the Middle East, Europe, North America and Latin America. The core components of this database mainly include:
Regulatory
- Interviews with top officials at regulatory agencies.
- Statistical data published by governments and regulatory agencies.
- Copies of telecom laws and amendments.
- Copies of tariff schedules, interconnection regulations and universal service requirements.
Operators
- Interviews with key officials in strategic planning, marketing, network planning and financial planning.
- Extensive surveys conducted with operators to determine key network statistics, investment, technology rollout plans, subscribers by service, tariff plans and service offerings.
- Internal statistics and bulletins published by operators.
Vendors
- Interviews with key officials within vendors both at in-country offices and in-company headquarters.

Contact US:

"India Smartphone Market to 2015: Mobile Handset Smartphone Sales by Vendor and by Operating System" report provides a top-level overview and detailed insights into the operating environment for mobile operators. It is an essential tool for companies active across the telecom value chain in India and for new companies that may be considering entering the market.

Visit Complete Report Here: http://www.marketresearchreports.biz/analysis-details/india-smartphone-market-to-2015-mobile-handset-smartphone-sales-by-vendor-and-by-operating-system

Key Findings
- Demographics - Statistical data on India population, households, businesses, nominal GDP, nominal GDP per Capita, consumer price inflation, exchange rates (local currency and US dollar)
- Mobile subscriptions and penetration by population
- Mobile handset sales by quarter
- Mobile handset revenue and average selling price
- Mobile handset sales volume by: type of customer, category, price band, air interface, vendor, operating system and feature
- Mobile smartphone handset sales by: venfor, operating system and by feature

Download Full Report with TOC: http://www.marketresearchreports.biz/sample/sample/198094

Synopsis
This report offers a concise breakdown of India operating environment, with both historic data and forecasts to 2015. The report contains quantitative data which covers:

- Demographics - data on India population, households, businesses, nominal GDP, nominal GDP per Capita, consumer price inflation, exchange rates (local currency and US dollar)
- Mobile subscriptions and penetration by population
- Mobile handset sales by quarter
- Mobile handset revenue and average selling price
- Mobile handset sales volume by: type of customer, category, price band, air interface, vendor, operating system and feature
- Mobile smartphone handset sales by: venfor, operating system and by feature

Since 1986, Pyramid Research has compiled an extensive database on the telecommunications markets in Asia, Africa, the Middle East, Europe, North America and Latin America. The core components of this database mainly include:
Browse Full Report With TOC: http://www.marketresearchreports.biz/analysis/198094

Regulatory
- Interviews with top officials at regulatory agencies.
- Statistical data published by governments and regulatory agencies.
- Copies of telecom laws and amendments.
- Copies of tariff schedules, interconnection regulations and universal service requirements.
Operators
- Interviews with key officials in strategic planning, marketing, network planning and financial planning.
- Extensive surveys conducted with operators to determine key network statistics, investment, technology rollout plans, subscribers by service, tariff plans and service offerings.
- Internal statistics and bulletins published by operators.
Vendors
- Interviews with key officials within vendors both at in-country offices and in-company headquarters.

Contact US: